{"id":745673,"date":"2018-08-30T15:05:00","date_gmt":"2018-08-30T15:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/"},"modified":"2025-11-07T01:27:05","modified_gmt":"2025-11-07T06:27:05","slug":"fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/","title":{"rendered":"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients"},"content":{"rendered":"<p class=\"bwalignc\">       Approvals Based on Findings from the Pivotal Phase 3 DRIVE-AHEAD and        DRIVE-FORWARD Trials Evaluating the Efficacy and Safety of DELSTRIGO and        PIFELTRO     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved two new HIV-1 medicines: DELSTRIGO<b>\u2122<\/b>, a once-daily<br \/>\n      fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC,<br \/>\n      300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO<b>\u2122<\/b><br \/>\n      (doravirine, 100 mg), a new non-nucleoside reverse transcriptase<br \/>\n      inhibitor (NNRTI) to be administered in combination with other<br \/>\n      antiretroviral medicines. Both DELSTRIGO and PIFELTRO are indicated for<br \/>\n      the treatment of HIV-1 infection in adult patients with no prior<br \/>\n      antiretroviral treatment experience, and are administered orally once<br \/>\n      daily with or without food. DELSTRIGO contains a boxed warning regarding<br \/>\n      post-treatment acute exacerbation of hepatitis B (HBV) infection.<br \/>\n      DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      DELSTRIGO and PIFELTRO are contraindicated when co-administered with<br \/>\n      drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as<br \/>\n      significant decreases in doravirine plasma concentrations may occur,<br \/>\n      which may decrease the effectiveness of DELSTRIGO and PIFELTRO.<br \/>\n      DELSTRIGO is contraindicated in patients with a previous<br \/>\n      hypersensitivity reaction to 3TC. For more information, see \u201cSelected<br \/>\n      Safety Information\u201d below.\n    <\/p>\n<p>\n      \u201cAs part of Merck\u2019s 30-year commitment to the care of people with HIV,<br \/>\n      we are pleased to now bring forward these two new antiretroviral<br \/>\n      treatment options, DELSTRIGO and PIFELTRO, which we believe offer a<br \/>\n      compelling clinical profile for clinicians and people living with HIV,\u201d<br \/>\n      said Dr. George Hanna, vice president and therapeutic area head of<br \/>\n      infectious diseases, Global Clinical Development, Merck Research<br \/>\n      Laboratories. \u201cWe are thankful to the researchers as well as those<br \/>\n      living with HIV and their communities for the collaboration that made<br \/>\n      today\u2019s approval possible.\u201d\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Renal impairment, including cases of<br \/>\n      acute renal failure and Fanconi syndrome, have been reported with the<br \/>\n      use of TDF. DELSTRIGO should be avoided with concurrent or recent use of<br \/>\n      a nephrotoxic agent, as cases of acute renal failure after initiation of<br \/>\n      high-dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs)<br \/>\n      have been reported in patients with risk factors for renal dysfunction<br \/>\n      who appeared stable on TDF.\n    <\/p>\n<p>\n      <b>Data Supporting the Approvals of DELSTRIGO (doravirine 100 mg\/3TC 300<br \/>\n      mg\/TDF 300 mg) and PIFELTRO (doravirine)<\/b><br \/>\n<br \/>The FDA approvals of<br \/>\n      DELSTRIGO, the once-daily fixed-dose combination tablet as a complete<br \/>\n      regimen, and PIFELTRO, a new NNRTI, are based on findings from the<br \/>\n      pivotal, randomized, multicenter, double-blind, active controlled Phase<br \/>\n      3 trials, DRIVE-AHEAD and DRIVE-FORWARD, evaluating the efficacy and<br \/>\n      safety of DELSTRIGO and PIFELTRO, respectively, in participants infected<br \/>\n      with HIV-1 with no antiretroviral treatment history.\n    <\/p>\n<p>\n      <i>The DRIVE-AHEAD Clinical Trial<\/i><br \/>\n<br \/>In DRIVE-AHEAD, 728<br \/>\n      participants with no antiretroviral treatment history were randomized<br \/>\n      and received at least one dose of either DELSTRIGO or<br \/>\n      efavirenz\/emtricitabine\/tenofovir disoproxil fumarate (EFV 600 mg\/FTC<br \/>\n      200 mg\/TDF 300 mg) once daily. DELSTRIGO demonstrated sustained viral<br \/>\n      suppression through 48 weeks, meeting its primary endpoint of<br \/>\n      non-inferior efficacy compared to EFV\/FTC\/TDF (84% in the DELSTRIGO<br \/>\n      group achieved viral suppression of HIV-1 RNA &lt;50 copies\/mL vs. 81% in<br \/>\n      the EFV\/FTC\/TDF group; treatment difference: 3.5%, [95% CI:] -2.0%,<br \/>\n      9.0%). Of the 21 percent of study participants with a high viral load at<br \/>\n      baseline (HIV-1 RNA &gt;100,000 copies\/mL), 77 percent in the DELSTRIGO<br \/>\n      group and 72 percent in the EFV\/FTC\/TDF group achieved HIV-1 RNA &lt;50<br \/>\n      copies\/mL at Week 48.\n    <\/p>\n<p>\n      At Week 48, DELSTRIGO-treated participants showed statistically<br \/>\n      significant superior lipid profiles as measured by changes from baseline<br \/>\n      in LDL-cholesterol and non-HDL-cholesterol (LDL-C: -2.1 mg\/dL in the<br \/>\n      DELSTRIGO group vs. 8.3 mg\/dL in the EFV\/FTC\/TDF group; treatment<br \/>\n      difference: -10.2 mg\/dL, [95% CI:] -13.8, -6.7, p&lt;0.0001; non-HDL-C:<br \/>\n      -4.1 mg\/dL in the DELSTRIGO group vs. 12.7 mg\/dL in EFV\/FTC\/TDF;<br \/>\n      treatment difference: -16.9 mg\/dL, [95% CI:] -20.8, -13.0, p&lt;0.0001).<br \/>\n      However, the clinical benefit of these findings has not been<br \/>\n      demonstrated. In addition, a statistically significant lower proportion<br \/>\n      of DELSTRIGO-treated participants compared to EFV\/FTC\/TDF-treated<br \/>\n      participants reported neuropsychiatric adverse events in the three<br \/>\n      pre-specified categories of dizziness (9% vs. 37%; treatment difference:<br \/>\n      -28.3%, [95% CI:] -34.0, -22.5, p &lt;0.001), sleep disorders and<br \/>\n      disturbances (12% vs. 26%; treatment difference: -13.5%, [95% CI:]<br \/>\n      -19.1, -7.9, p &lt;0.001), and altered sensorium (4% vs. 8%; treatment<br \/>\n      difference: -3.8%, [95% CI:] -7.6, -0.3, p=0.033).\n    <\/p>\n<p>\n      The rate of discontinuation of treatment due to adverse events was lower<br \/>\n      in the DELSTRIGO treatment group than in the EFV\/FTC\/TDF treatment<br \/>\n      group&nbsp;(3% and 6%, respectively). Clinical adverse reactions of all<br \/>\n      grades occurring in \u22655 percent of participants in the DELSTRIGO<br \/>\n      treatment group included dizziness (7%), nausea (5%) and abnormal dreams<br \/>\n      (5%). No adverse reactions of Grade 2 or higher (moderate or severe)<br \/>\n      occurred in \u22652 percent of participants treated with DELSTRIGO.\n    <\/p>\n<p>\n      <i>The DRIVE-FORWARD Clinical Trial<\/i><br \/>\n<br \/>In DRIVE-FORWARD, 766<br \/>\n      participants with no antiretroviral treatment history were randomized<br \/>\n      and received at least one dose of either PIFELTRO once daily or<br \/>\n      darunavir 800 mg + ritonavir 100 mg (DRV+r) once daily, each in<br \/>\n      combination with emtricitabine (FTC)\/TDF or abacavir (ABC)\/3TC selected<br \/>\n      by the investigator. PIFELTRO demonstrated sustained viral suppression<br \/>\n      through 48 weeks, meeting its primary endpoint of non-inferior efficacy<br \/>\n      compared to DRV+r, each in combination with FTC\/TDF or ABC\/3TC (84% in<br \/>\n      the PIFELTRO group achieved viral suppression of HIV-1 RNA &lt;50 copies\/mL<br \/>\n      vs. 80% in the DRV+r group; treatment difference: 3.9%, [95% CI:] -1.6%,<br \/>\n      9.4%). Of the 20 percent of study participants with a high viral load at<br \/>\n      baseline (HIV-1 RNA &gt;100,000 copies\/mL), 77 percent in the PIFELTRO<br \/>\n      group and 74 percent in the DRV+r group achieved HIV-1 RNA &lt;50 copies\/mL<br \/>\n      at Week 48.\n    <\/p>\n<p>\n      At Week 48, PIFELTRO-treated participants showed statistically<br \/>\n      significant superior lipid profiles as measured by changes from baseline<br \/>\n      in LDL-cholesterol and non-HDL-cholesterol (LDL-C: -4.6 mg\/dL in the<br \/>\n      PIFELTRO group vs. 9.5 mg\/dL in the DRV+r group; treatment difference:<br \/>\n      -14.4 mg\/dL, [95% CI:] -18.0, -10.8, p&lt;0.0001; non-HDL-C: -5.4 mg\/DL in<br \/>\n      the PIFELTRO group vs. 13.7 mg\/dL in the DRV+r group, treatment<br \/>\n      difference: -19.4 mg\/dL, [95% CI:] -23.4, -15.4, p&lt;0.0001). However, the<br \/>\n      clinical benefit of these findings has not been demonstrated.\n    <\/p>\n<p>\n      The rate of discontinuation of therapy due to adverse events in either<br \/>\n      treatment group was low&nbsp;(2% in the PIFELTRO group and 3% in the DRV+r<br \/>\n      group). Clinical adverse reactions of all grades occurring in \u22655 percent<br \/>\n      of participants in the PIFELTRO treatment group included nausea (7%),<br \/>\n      headache (6%), fatigue (6%), diarrhea (5%) and abdominal pain (5%). No<br \/>\n      adverse reactions of Grade 2 or higher (moderate or severe) occurred in<br \/>\n      \u22652 percent of participants treated with PIFELTRO.\n    <\/p>\n<p>\n      \u201cAs a result of the remarkable strides made in the fight against HIV,<br \/>\n      clinicians and their patients have the opportunity to work together to<br \/>\n      identify treatment regimens that may be best for each individual, taking<br \/>\n      into account other aspects of that person\u2019s health, including other<br \/>\n      medicines they may be taking,\u201d said Dr. David Wohl, professor, Division<br \/>\n      of Infectious Diseases, University of North Carolina (UNC) Chapel Hill<br \/>\n      School of Medicine and site leader, UNC AIDS Clinical Trials<br \/>\n      Unit.&nbsp;\u201cToday\u2019s approvals of DELSTRIGO and PIFELTRO provide two new<br \/>\n      options for the treatment of HIV-1 in appropriate treatment-na\u00efve adult<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      DELSTRIGO and PIFELTRO can be co-administered with a wide range of<br \/>\n      non-antiretroviral agents, and PIFELTRO can be co-administered with a<br \/>\n      wide range of antiretroviral agents. DELSTRIGO and PIFELTRO cannot be<br \/>\n      co-administered with enzalutamide, carbamazepine, oxcarbazepine,<br \/>\n      phenobarbital, phenytoin, rifampin, rifapentine, mitotane or St. John\u2019s<br \/>\n      wort. If DELSTRIGO is co-administered with rifabutin, patients should<br \/>\n      take one tablet of DELSTRIGO once daily, followed by one tablet of<br \/>\n      doravirine (PIFELTRO) approximately 12 hours after the dose of<br \/>\n      DELSTRIGO. If PIFELTRO is co-administered with rifabutin, patients need<br \/>\n      to increase the PIFELTRO dosage to one tablet twice daily approximately<br \/>\n      12 hours apart. Use of PIFELTRO with efavirenz, etravirine, or<br \/>\n      nevirapine is not recommended.\n    <\/p>\n<p>\n      No clinically significant changes in concentration have been observed<br \/>\n      following the co-administration of doravirine and the following drugs:<br \/>\n      dolutegravir, ritonavir, TDF, 3TC, elbasvir and grazoprevir, ledipasvir<br \/>\n      and sofosbuvir, ketoconazole, aluminum hydroxide\/magnesium<br \/>\n      hydroxide\/simethicone containing antacid, pantoprazole, atorvastatin, an<br \/>\n      oral contraceptive containing ethinyl estradiol and levonorgestrel,<br \/>\n      metformin, methadone, and midazolam. For DELSTRIGO, no clinically<br \/>\n      significant drug interactions have been observed in studies conducted in<br \/>\n      healthy participants between TDF and the following medications:<br \/>\n      entecavir, methadone, oral contraceptives, sofosbuvir or tacrolimus. If<br \/>\n      DELSTRIGO is co-administered with ledipasvir\/sofosbuvir or<br \/>\n      sofosbuvir\/velpatasvir, monitor for adverse reactions associated with<br \/>\n      TDF. Co-administration of single doses of 3TC and sorbitol resulted in a<br \/>\n      sorbitol dose-dependent reduction in 3TC exposures. When possible, avoid<br \/>\n      use of sorbitol-containing medicines with 3TC-containing medicines, such<br \/>\n      as DELSTRIGO.\n    <\/p>\n<p>\n      <b>Overall Viral Resistance Profile<\/b><br \/>\n<br \/>In the DELSTRIGO and<br \/>\n      PIFELTRO treatment arms of the DRIVE-AHEAD and DRIVE-FORWARD trials<br \/>\n      (n=747), a total of 11 participants showed the emergence of<br \/>\n      doravirine-associated resistance substitutions, among the 28<br \/>\n      participants in the resistance analysis subset (participants with HIV-1<br \/>\n      RNA &gt;400 copies per mL at virologic failure or early study<br \/>\n      discontinuation and having resistance data). Of these 11 participants,<br \/>\n      seven showed both genotypic and phenotypic resistance to doravirine,<br \/>\n      with at least a 100-fold reduction in susceptibility to doravirine. The<br \/>\n      other four participants had substitutions that were associated with less<br \/>\n      than twofold reduction in susceptibility to doravirine.\n    <\/p>\n<p>\n      In the EFV\/FTC\/TDF treatment arm of the DRIVE-AHEAD trial (n=364), 12<br \/>\n      participants showed the emergence of efavirenz-associated resistance<br \/>\n      substitutions among 20 participants in the resistance analysis subset.<br \/>\n      In the DRV+r treatment arm of the DRIVE-FORWARD trial (n=383), no<br \/>\n      participants showed the emergence of DRV+r associated resistance<br \/>\n      substitutions among the nine participants with resistance data.\n    <\/p>\n<p>\n      Cross-resistance has been observed among NNRTIs, including doravirine.<br \/>\n      Treatment-emergent doravirine resistance-associated substitutions can<br \/>\n      confer cross-resistance to efavirenz, rilpivirine, nevirapine and<br \/>\n      etravirine. No significant cross-resistance has been demonstrated<br \/>\n      between doravirine-resistant HIV-1 variants and 3TC, FTC or tenofovir or<br \/>\n      between 3TC or tenofovir-resistant variants and doravirine.\n    <\/p>\n<p>\n      \u201cToday, with the right access and care, people living with HIV are<br \/>\n      better able to manage this chronic condition,\u201d said Kathie Hiers, chief<br \/>\n      executive officer, AIDS Alabama. \u201cWe are thankful for Merck\u2019s unwavering<br \/>\n      commitment to help address unmet needs through the development of new<br \/>\n      treatment options, and the provision of community support and<br \/>\n      educational resources for people living with HIV.\u201d\n    <\/p>\n<p>\n      <b>DELSTRIGO (doravirine\/3TC\/TDF) and PIFELTRO (doravirine) Availability<br \/>\n      and Access<\/b><br \/>\n<br \/>The approvals of DELSTRIGO and PIFELTRO come ahead<br \/>\n      of the original FDA target action date of Oct. 23, 2018. Merck<br \/>\n      anticipates that PIFELTRO and DELSTRIGO will be stocked through<br \/>\n      wholesalers within one month. Merck is working to obtain access for<br \/>\n      patients in government-sponsored programs, including Medicare Part D,<br \/>\n      Medicaid and AIDS Drug Assistance Programs. Upon approval, DELSTRIGO and<br \/>\n      PIFELTRO will be covered products under the Merck Patient Assistance<br \/>\n      Program and will be available to eligible patients when the medicines<br \/>\n      are available. Doravirine is also under regulatory review by the<br \/>\n      European Medicines Agency (EMA).\n    <\/p>\n<p>\n      <b>Selected Safety Information about DELSTRIGO (doravirine\/3TC\/TDF)<\/b><br \/>\n<br \/>\n<i>Warning:<br \/>\n      Post treatment Acute Exacerbation of Hepatitis B (HBV)<\/i><br \/>\n<br \/>All<br \/>\n      patients with HIV-1 should be tested for the presence of HBV before<br \/>\n      initiating antiretroviral therapy. Severe acute exacerbations of HBV<br \/>\n      have been reported in patients who are coinfected with HIV-1 and HBV and<br \/>\n      have discontinued products containing lamivudine or TDF, which are<br \/>\n      components of DELSTRIGO. Patients coinfected with HIV-1 and HBV who<br \/>\n      discontinue DELSTRIGO should be monitored with both clinical and<br \/>\n      laboratory follow-up for at least several months after stopping<br \/>\n      DELSTRIGO. If appropriate, initiation of anti-HBV therapy may be<br \/>\n      warranted.\n    <\/p>\n<p>\n      DELSTRIGO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (Hypericum<br \/>\n      perforatum)), as significant decreases in doravirine plasma<br \/>\n      concentrations may occur, which may decrease the effectiveness of<br \/>\n      DELSTRIGO. DELSTRIGO is contraindicated in patients with a previous<br \/>\n      hypersensitivity reaction to lamivudine.\n    <\/p>\n<p>\n      Renal impairment, including cases of acute renal failure and Fanconi<br \/>\n      syndrome, have been reported with the use of TDF. DELSTRIGO should be<br \/>\n      avoided with concurrent or recent use of a nephrotoxic agent, as cases<br \/>\n      of acute renal failure after initiation of high-dose or multiple NSAIDs<br \/>\n      have been reported in patients with risk factors for renal dysfunction<br \/>\n      who appeared stable on TDF.\n    <\/p>\n<p>\n      Prior to or when initiating DELSTRIGO, and during treatment, assess<br \/>\n      serum creatinine, estimated creatinine clearance, urine glucose and<br \/>\n      urine protein in all patients. In patients with chronic kidney disease,<br \/>\n      also assess serum phosphorus. Discontinue DELSTRIGO in patients who<br \/>\n      develop clinically significant decreases in renal function or evidence<br \/>\n      of Fanconi syndrome. Discontinue DELSTRIGO if estimated creatinine<br \/>\n      clearance declines below 50 mL\/min.\n    <\/p>\n<p>\n      In clinical trials in HIV-1 infected adults, TDF was associated with<br \/>\n      slightly greater decreases in bone mineral density (BMD) and increases<br \/>\n      in biochemical markers of bone metabolism. Serum parathyroid hormone<br \/>\n      levels and 1,25 vitamin D levels were also higher. Cases of osteomalacia<br \/>\n      associated with proximal renal tubulopathy have been reported with the<br \/>\n      use of TDF.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Because DELSTRIGO is a complete<br \/>\n      regimen, co-administration with other antiretroviral medications for the<br \/>\n      treatment of HIV-1 infection is not recommended.\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions.\n    <\/p>\n<p>\n      If co-administered with rifabutin, take one tablet of DELSTRIGO once<br \/>\n      daily, followed by one tablet of doravirine (PIFELTRO) approximately 12<br \/>\n      hours after the dose of DELSTRIGO. The most common adverse reactions<br \/>\n      with DELSTRIGO (incidence \u22655%, all intensities) were dizziness (7%),<br \/>\n      nausea (5%) and abnormal dreams (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to DELSTRIGO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      DELSTRIGO due to the potential for HIV-1 transmission. Because DELSTRIGO<br \/>\n      is a fixed-dose combination tablet and the components cannot be altered,<br \/>\n      it is not recommended in patients with estimated creatinine clearance<br \/>\n      less than 50 mL\/min.\n    <\/p>\n<p>\n      <b>Selected Safety Information about PIFELTRO (doravirine)<\/b><br \/>\n<br \/>PIFELTRO<br \/>\n      is contraindicated when co-administered with drugs that are strong<br \/>\n      cytochrome P450 (CYP)3A enzyme inducers (including the anticonvulsants<br \/>\n      carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen<br \/>\n      receptor inhibitor enzalutamide; the antimycobacterials rifampin and<br \/>\n      rifapentine; the cytotoxic agent mitotane; and the herbal product St.<br \/>\n      John\u2019s wort (Hypericum perforatum)), as significant decreases in<br \/>\n      PIFELTRO plasma concentrations may occur, which may decrease the<br \/>\n      effectiveness of PIFELTRO. Immune reconstitution syndrome can occur,<br \/>\n      including the occurrence of autoimmune disorders with variable time to<br \/>\n      onset, which may necessitate further evaluation and treatment.<br \/>\n      Co-administration of PIFELTRO with efavirenz, etravirine or nevirapine<br \/>\n      is not recommended. If co-administered with rifabutin, increase PIFELTRO<br \/>\n      dosage to one tablet twice daily (approximately 12 hours apart).\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions. The safety of PIFELTRO<br \/>\n      is based on two studies, DRIVE-FORWARD and DRIVE-AHEAD. In<br \/>\n      DRIVE-FORWARD, the most common adverse reactions (incidence \u22655%, all<br \/>\n      intensities) were nausea (7%), headache (6%), fatigue (6%), diarrhea<br \/>\n      (5%) and abdominal pain (5%). In DRIVE-AHEAD, the most common adverse<br \/>\n      reactions (incidence \u22655%, all intensities) were dizziness (7%), abnormal<br \/>\n      dreams (5%) and nausea (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to PIFELTRO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      PIFELTRO due to the potential for HIV transmission.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world&#8217;s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer&#8217;s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\/\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for DELSTRIGO (doravirine\/3TC\/TDF)<br \/>\n      at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<br \/>\n<b>Patient<br \/>\n      Information for DELSTRIGO (doravirine\/3TC\/TDF) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf<\/b><br \/>\n<\/a><br \/>\n<br \/>\n<b>Please<br \/>\n      see Prescribing Information for PIFELTRO (doravirine) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<br \/>\n<b>Patient<br \/>\n      Information for PIFELTRO (doravirine) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180830005793r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Sarra S.        Herzog, 908-740-1871<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved two new HIV-1 medicines: DELSTRIGO \u2122 , a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO \u2122 (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. Both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, and are administered orally once daily with or without food. DELSTRIGO contains a boxed warning regarding post-treatment acute exacerbation of hepatitis B (HBV) infection. DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS. DELSTRIGO and PIFELTRO are contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745673","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved two new HIV-1 medicines: DELSTRIGO \u2122 , a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO \u2122 (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. Both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, and are administered orally once daily with or without food. DELSTRIGO contains a boxed warning regarding post-treatment acute exacerbation of hepatitis B (HBV) infection. DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS. DELSTRIGO and PIFELTRO are contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\\\/\",\"name\":\"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-08-30T15:05:00+00:00\",\"dateModified\":\"2025-11-07T06:27:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved two new HIV-1 medicines: DELSTRIGO \u2122 , a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO \u2122 (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. Both DELSTRIGO and PIFELTRO are indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, and are administered orally once daily with or without food. DELSTRIGO contains a boxed warning regarding post-treatment acute exacerbation of hepatitis B (HBV) infection. DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS. DELSTRIGO and PIFELTRO are contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:05+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/","name":"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-08-30T15:05:00+00:00","dateModified":"2025-11-07T06:27:05+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-dorav\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Merck\u2019s DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO\u2122 (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d89d37a2-b041-4520-b13d-dcfcde58f0c3","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Approves-Mercks-DELSTRIGO-doravirine--lamivudine--tenofovir-disoproxil-fumarate-a-Once-Daily-Fixed-Dose-Combination-Tablet-as-a-C-9O0LC.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745673\/revisions"}],"predecessor-version":[{"id":3675021,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745673\/revisions\/3675021"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745673"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}